BRAF and melanoma: In those treated with the T cell checkpoint inhibitor ipilimumab, approximately 21% of patients survive in the very long term and checkpoint inhibiting PD-1 antibody nivolumab recently demonstrated a 30% increase of 1-year survival rate compared to DTIC in BRAF wild-type advanced melanoma patients [21].